Global Postmenopausal Vaginal Atrophy Drugs Market Research Report 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 10188

Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.

The global Postmenopausal Vaginal Atrophy Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Postmenopausal Vaginal Atrophy Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Postmenopausal Vaginal Atrophy Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.

Segment by Regions
North America
Europe
China
Japan

Segment by Type
by Estrogen-Based Drugs
Premarin
Vagifem
Estrace
Estring
Femring
by Non-Estrogen-Based Drugs
BZA/CE
Osphena
Vaginorm

Segment by Application
Vaginal Gels
Creams
Tablets
Rings
Patches

Table of Contents

Executive Summary
1 Postmenopausal Vaginal Atrophy Drugs Market Overview
1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy Drugs
1.2 Postmenopausal Vaginal Atrophy Drugs Segment by Estrogen-Based Drugs
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Production Growth Rate Comparison by Estrogen-Based Drugs (2014-2025)
1.2.2 Premarin
1.2.3 Vagifem
1.2.4 Estrace
1.2.5 Estring
1.2.6 Femring
1.3 Postmenopausal Vaginal Atrophy Drugs Segment by Application
1.3.1 Postmenopausal Vaginal Atrophy Drugs Consumption Comparison by Application (2014-2025)
1.3.2 Vaginal Gels
1.3.3 Creams
1.3.4 Tablets
1.3.5 Rings
1.3.6 Patches
1.4 Global Postmenopausal Vaginal Atrophy Drugs Market by Region
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Region
1.4.2 North America Status and Prospect (2014-2025)
1.4.3 Europe Status and Prospect (2014-2025)
1.4.4 China Status and Prospect (2014-2025)
1.4.5 Japan Status and Prospect (2014-2025)
1.5 Global Postmenopausal Vaginal Atrophy Drugs Market Size
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue (2014-2025)
1.5.2 Global Postmenopausal Vaginal Atrophy Drugs Production (2014-2025)

2 Global Postmenopausal Vaginal Atrophy Drugs Market Competition by Manufacturers
2.1 Global Postmenopausal Vaginal Atrophy Drugs Production Market Share by Manufacturers (2014-2019)
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2014-2019)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Postmenopausal Vaginal Atrophy Drugs Production Sites, Area Served, Product Types
2.5 Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation and Trends
2.5.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate
2.5.2 Postmenopausal Vaginal Atrophy Drugs Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Postmenopausal Vaginal Atrophy Drugs Production Market Share by Regions
3.1 Global Postmenopausal Vaginal Atrophy Drugs Production Market Share by Regions
3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Regions (2014-2019)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Postmenopausal Vaginal Atrophy Drugs Production
3.4.1 North America Postmenopausal Vaginal Atrophy Drugs Production Growth Rate (2014-2019)
3.4.2 North America Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe Postmenopausal Vaginal Atrophy Drugs Production
3.5.1 Europe Postmenopausal Vaginal Atrophy Drugs Production Growth Rate (2014-2019)
3.5.2 Europe Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.6 China Postmenopausal Vaginal Atrophy Drugs Production (2014-2019)
3.6.1 China Postmenopausal Vaginal Atrophy Drugs Production Growth Rate (2014-2019)
3.6.2 China Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.7 Japan Postmenopausal Vaginal Atrophy Drugs Production (2014-2019)
3.7.1 Japan Postmenopausal Vaginal Atrophy Drugs Production Growth Rate (2014-2019)
3.7.2 Japan Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Postmenopausal Vaginal Atrophy Drugs Consumption by Regions
4.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption by Regions
4.2 North America Postmenopausal Vaginal Atrophy Drugs Consumption (2014-2019)
4.3 Europe Postmenopausal Vaginal Atrophy Drugs Consumption (2014-2019)
4.4 China Postmenopausal Vaginal Atrophy Drugs Consumption (2014-2019)
4.5 Japan Postmenopausal Vaginal Atrophy Drugs Consumption (2014-2019)

5 Global Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price Trend by Type
5.1 Global Postmenopausal Vaginal Atrophy Drugs Production Market Share by Type (2014-2019)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2014-2019)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2014-2019)
5.4 Global Postmenopausal Vaginal Atrophy Drugs Production Growth by Type (2014-2019)

6 Global Postmenopausal Vaginal Atrophy Drugs Market Analysis by Applications
6.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Market Share by Application (2014-2019)
6.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Postmenopausal Vaginal Atrophy Drugs Business
7.1 Actavis plc
7.1.1 Actavis plc Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.1.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.1.4 Main Business and Markets Served
7.2 Bionovo, Inc.
7.2.1 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.2.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.2.4 Main Business and Markets Served
7.3 Endoceutics, Inc.
7.3.1 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.3.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.3.4 Main Business and Markets Served
7.4 Novo Nordisk A/S
7.4.1 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.4.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.4.4 Main Business and Markets Served
7.5 Pfizer Inc.
7.5.1 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.5.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.5.4 Main Business and Markets Served
7.6 Teva Pharmaceuticals Ltd.
7.6.1 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.6.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.6.4 Main Business and Markets Served
7.7 Therapeutics MD, Inc.
7.7.1 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.7.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.7.4 Main Business and Markets Served
7.8 Shionogi & Company
7.8.1 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.8.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.8.4 Main Business and Markets Served
7.9 Allergan plc
7.9.1 Allergan plc Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.9.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.9.4 Main Business and Markets Served
7.10 Shionogi & Co. Ltd.
7.10.1 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Production Sites and Area Served
7.10.2 Postmenopausal Vaginal Atrophy Drugs Product Introduction, Application and Specification
7.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.10.4 Main Business and Markets Served

8 Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Analysis
8.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
8.4 Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.2 Postmenopausal Vaginal Atrophy Drugs Distributors List
9.3 Postmenopausal Vaginal Atrophy Drugs Customers

10 Market Dynamics
10.1 Market Trends
10.2 Opportunities
10.3 Market Drivers
10.4 Challenges
10.5 Influence Factors

11 Global Postmenopausal Vaginal Atrophy Drugs Market Forecast
11.1 Global Postmenopausal Vaginal Atrophy Drugs Production, Revenue Forecast
11.1.1 Global Postmenopausal Vaginal Atrophy Drugs Production Growth Rate Forecast (2019-2025)
11.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate Forecast (2019-2025)
11.1.3 Global Postmenopausal Vaginal Atrophy Drugs Price and Trend Forecast (2019-2025)
11.2 Global Postmenopausal Vaginal Atrophy Drugs Production Forecast by Regions (2019-2025)
11.2.1 North America Postmenopausal Vaginal Atrophy Drugs Production, Revenue Forecast (2019-2025)
11.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Production, Revenue Forecast (2019-2025)
11.2.3 China Postmenopausal Vaginal Atrophy Drugs Production, Revenue Forecast (2019-2025)
11.2.4 Japan Postmenopausal Vaginal Atrophy Drugs Production, Revenue Forecast (2019-2025)
11.3 Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Regions (2019-2025)
11.3.1 North America Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2019-2025)
11.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2019-2025)
11.3.3 China Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2019-2025)
11.3.4 Japan Postmenopausal Vaginal Atrophy Drugs Consumption Forecast (2019-2025)
11.4 Global Postmenopausal Vaginal Atrophy Drugs Production, Revenue and Price Forecast by Type (2019-2025)
11.5 Global Postmenopausal Vaginal Atrophy Drugs Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer